右美托咪定与阿片类药物配伍稳定性的初步考察  

Preliminary Study on Compatible Stability of Dexmedetomidine with Opioid Drugs

作　　者：刘遂库[1] 史海贤 门利玲 刘清[1] 吴玉霞[1] 

机构地区：[1]江苏恒瑞医药股份有限公司恒瑞医药研究院,江苏连云港222047

出　　处：《中国药师》2015年第6期1063-1065,共3页China Pharmacist

摘　　要：目的:研究右美托咪定分别与3种阿片类药物(舒芬太尼、芬太尼和布托啡诺)联合用药时的稳定性,以供临床合理用药参考。方法:右美托咪定分别与阿片类药物舒芬太尼、芬太尼及布托啡诺配伍,配制在0.9%氯化钠注射液中,室温放置,在0,24,48和96 h分别取样,进行性状、pH、不溶性微粒检查,并进行质谱检测。结果:在96 h内,配伍溶液均澄清透明,pH稳定,不溶性微粒检查符合规定,质谱检测显示无新物质生成。结论:3种配伍用药方案安全、合理、具有临床可行性。Objective： To study the stability of dexmedetomidine combined with three opioid drugs （ sufentanil, fentanil and butorphanol） in order to guide the reasonable clinical prescription. Methods： Dexmedetomidine was respectively combined with sufentanil, fentanil and butorphanol in 0.9% sodium chloride injection. The mixture was stored at room temperature for 0, 24, 48 and 96h, and then withdrawn for the detection of appearance, pH value, insoluble particles, and the analysis of mass spectrometry was performed. Results： Within 96 h, the prepared solutions were clear and transparent with stable pH value and qualified insoluble particles, and the results of mass spectrometry showed no new substance was generated. Conclusion： The three combination schemes are safe, reasonable and feasible in clinical application.

关 键 词：右美托咪定 阿片类药物 舒芬太尼 芬太尼 布托啡诺 联合用药 稳定性 

分 类 号：R942[医药卫生—药剂学]